News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
165 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (3218)
February (3391)
March (3462)
April (3660)
May (4667)
June (3468)
July (2307)
August (2524)
September (2745)
October (3357)
November (3389)
December (2298)
Day
1 (169)
2 (155)
3 (125)
4 (98)
7 (129)
8 (161)
9 (169)
10 (165)
11 (61)
14 (83)
15 (187)
16 (122)
17 (182)
18 (85)
20 (6)
21 (131)
22 (103)
23 (159)
24 (166)
25 (164)
28 (156)
29 (195)
30 (196)
31 (190)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
7
8
9
10
11
14
15
16
17
18
20
21
22
23
24
25
28
29
30
31
Vistagen
Telix Pharmaceuticals
Remix Therapeutics
Mediar Therapeutics
Insitro
Vor Bio
ProFound Therapeutics
Incyte
Afton Scientific LLC
Prostate cancer
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, potentially covering all patients with metastatic castration-resistant prostate cancer regardless of biomarker status.
October 10, 2024
·
2 min read
·
Tristan Manalac
1 of 17
Next
